{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T10:05:24Z","timestamp":1784887524491,"version":"3.55.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T00:00:00Z","timestamp":1736121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T00:00:00Z","timestamp":1736121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100005192","name":"California HIV\/AIDS Research Program","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005192","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["K24AI167805"],"award-info":[{"award-number":["K24AI167805"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Point-of-care HIV viral load testing may enhance patient care and improve HIV health services. We aimed to evaluate the feasibility and acceptability of implementing such testing in a high-volume community sexual health clinic in the United States.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We conducted a cross-sectional, mixed-methods study. Remnant venipuncture specimens from clients undergoing HIV and other sexual health screenings were analyzed using the Xpert<jats:sup>\u00ae<\/jats:sup> HIV-1 Viral Load assay. Results were compared to COBAS<jats:sup>\u00ae<\/jats:sup> AmpliPrep\/COBAS<jats:sup>\u00ae<\/jats:sup> TaqMan<jats:sup>\u00ae<\/jats:sup> HIV-1 Test. Clinical staff observations, study meeting notes, and two semi-structured in-depth interviews with clinical staff were used to understand perspectives on incorporating this testing into clinical practice.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We analyzed 113 samples from 111 clients. The Xpert assay showed excellent agreement with COBAS, with no clinically significant difference in viral load measurements. Clinical staff found Xpert testing acceptable, based on its ability to provide rapid, accurate test results and potential for bridging patient care gaps. Respondents noted that this testing would be particularly beneficial for individuals in whom barriers to care engagement may complicate follow-up. Challenges in implementation included machine errors as well as concerns related to staff workload, testing logistics, and the need for comprehensive equipment training.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This study represents the first effort in the United States to describe the feasibility of HIV viral load point-of-care testing in routine care. While the Xpert demonstrated comparable results to standard-of-care testing and staff found it acceptable, further work is needed to develop the workflow and implementation strategies that would enable real-time use and improved patient care.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Clinical trial<\/jats:title>\n                <jats:p>Not applicable.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-024-10384-2","type":"journal-article","created":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T09:19:30Z","timestamp":1736155170000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Feasibility and staff acceptability of implementing Xpert HIV-1 viral load point-of-care testing: a pilot study in San Francisco"],"prefix":"10.1186","volume":"25","author":[{"given":"Kelvin","family":"Moore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noelle Le","family":"Tourneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmin","family":"Alvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santos","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janessa","family":"Broussard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-C\u00e9dric","family":"Crouch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Roman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Defechereux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Bena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly A.","family":"Koester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lissa","family":"Moran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Pilcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Grant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katerina A.","family":"Christopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,6]]},"reference":[{"issue":"7297","key":"10384_CR1","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1136\/bmj.322.7297.1285","volume":"322","author":"CP Price","year":"2001","unstructured":"Price CP. Point of care testing. BMJ. 2001;322(7297):1285\u20138.","journal-title":"BMJ"},{"key":"10384_CR2","doi-asserted-by":"publisher","unstructured":"Drain PK, Dorward J, Bender A, et al. Point-of-care HIV viral load testing: an essential Tool for a sustainable global HIV\/AIDS response. Clin Microbiol Rev. 2019;32(3). https:\/\/doi.org\/10.1128\/cmr.00097-18.","DOI":"10.1128\/cmr.00097-18"},{"issue":"9","key":"10384_CR3","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1177\/0956462420923883","volume":"31","author":"G Whitlock","year":"2020","unstructured":"Whitlock G, Nwokolo N. Does qualitative viral load testing shorten the window period for diagnosing HIV in individuals attending for post-exposure prophylaxis? Int J STD AIDS. 2020;31(9):816\u20139. https:\/\/doi.org\/10.1177\/0956462420923883.","journal-title":"Int J STD AIDS"},{"issue":"S1","key":"10384_CR4","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/hiv.12595","volume":"19","author":"M Meulbroek","year":"2018","unstructured":"Meulbroek M, Pujol F, P\u00e9rez F, et al. BCN Checkpoint: same-day confirmation of reactive HIV rapid test with point of Care HIV-RNA accelerates linkage to care and reduces anxiety. HIV Med. 2018;19(S1):63\u20135. https:\/\/doi.org\/10.1111\/hiv.12595.","journal-title":"HIV Med"},{"key":"10384_CR5","unstructured":"Prequalified In Vitro Diagnostics. WHO - Prequalification of Medical Products (IVDs, Medicines, Vaccines and Immunization Devices, Vector Control). January 27, 2020. Accessed August 21. 2023. https:\/\/extranet.who.int\/pqweb\/vitro-diagnostics\/vitro-diagnostics-lists"},{"issue":"6","key":"10384_CR6","doi-asserted-by":"publisher","first-page":"e0218369","DOI":"10.1371\/journal.pone.0218369","volume":"14","author":"CA Agutu","year":"2019","unstructured":"Agutu CA, Ngetsa CJ, Price MA, et al. Systematic review of the performance and clinical utility of point of care HIV-1 RNA testing for diagnosis and care. PLoS ONE. 2019;14(6):e0218369. https:\/\/doi.org\/10.1371\/journal.pone.0218369.","journal-title":"PLoS ONE"},{"issue":"4","key":"10384_CR7","doi-asserted-by":"publisher","first-page":"e25487","DOI":"10.1002\/jia2.25487","volume":"23","author":"T Kufa","year":"2020","unstructured":"Kufa T, Mazanderani AH, Sherman GG, et al. Point-of\u2010care HIV maternal viral load and early infant diagnosis testing around time of delivery at tertiary obstetric units in South Africa: a prospective study of coverage, results return and turn\u2010around times. J Int AIDS Soc. 2020;23(4):e25487. https:\/\/doi.org\/10.1002\/jia2.25487.","journal-title":"J Int AIDS Soc"},{"issue":"4","key":"10384_CR8","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1097\/QAI.0000000000002267","volume":"83","author":"F Moyo","year":"2020","unstructured":"Moyo F, Haeri Mazanderani A, Murray T, et al. Characterizing viral load Burden among HIV-Infected women around the time of delivery: findings from four Tertiary Obstetric Units in Gauteng, South Africa. JAIDS J Acquir Immune Defic Syndr. 2020;83(4):390. https:\/\/doi.org\/10.1097\/QAI.0000000000002267.","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"key":"10384_CR9","doi-asserted-by":"publisher","first-page":"136","DOI":"10.11604\/pamj.2022.42.136.32041","volume":"42","author":"PY S\u00e8ne","year":"2022","unstructured":"S\u00e8ne PY, Diop-Ndiaye H, Ndoye AS, et al. Performance of Xpert HIV-1 viral load test in Senegal: a country of high circulation of CRF02_AG. Pan Afr Med J. 2022;42:136. https:\/\/doi.org\/10.11604\/pamj.2022.42.136.32041.","journal-title":"Pan Afr Med J"},{"issue":"5","key":"10384_CR10","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1097\/QAI.0000000000003212","volume":"93","author":"J Dorward","year":"2023","unstructured":"Dorward J, Sookrajh Y, Lessells R, et al. Point-of-care viral load testing to manage HIV Viremia during the Rollout of Dolutegravir-based ART in South Africa: a Randomized Feasibility Study (POwER). J Acquir Immune Defic Syndr. 2023;93(5):403\u201312. https:\/\/doi.org\/10.1097\/QAI.0000000000003212.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10384_CR11","unstructured":"Technical Update for HIV Nucleic Acid Tests Approved for Diagnostic Purposes. May 16. 2023. Accessed February 22, 2024. https:\/\/www.cdc.gov\/hiv\/guidelines\/recommendations\/technical-update-for-hiv.html"},{"issue":"6","key":"10384_CR12","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1097\/QAD.0000000000003494","volume":"37","author":"VA Fonner","year":"2023","unstructured":"Fonner VA, Ridgeway K, van der Straten A, et al. Safety and efficacy of long-acting injectable cabotegravir as preexposure prophylaxis to prevent HIV acquisition. AIDS. 2023;37(6):957\u201366. https:\/\/doi.org\/10.1097\/QAD.0000000000003494.","journal-title":"AIDS"},{"issue":"12","key":"10384_CR13","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1093\/infdis\/jiac415","volume":"226","author":"SH Eshleman","year":"2022","unstructured":"Eshleman SH, Fogel JM, Halvas EK, et al. HIV RNA screening reduces integrase strand transfer inhibitor resistance risk in persons receiving long-acting cabotegravir for HIV Prevention. J Infect Dis. 2022;226(12):2170\u201380. https:\/\/doi.org\/10.1093\/infdis\/jiac415.","journal-title":"J Infect Dis"},{"key":"10384_CR14","doi-asserted-by":"publisher","unstructured":"Fogel JM, Piwowar-Manning E, Moser A et al. Evaluation of xpert point-of-care assays for detection of HIV infection in persons using long-acting cabotegravir for pre-exposure prophylaxis. Microbiol Spectr. 12(8):e00307\u201324. https:\/\/doi.org\/10.1128\/spectrum.00307-24","DOI":"10.1128\/spectrum.00307-24"},{"key":"10384_CR15","doi-asserted-by":"publisher","unstructured":"Bacon OML, Coffey SC, Hsu LC, Chin JCS, Havlir DV, Buchbinder SP. Development of a Citywide Rapid Antiretroviral Therapy Initiative in San Francisco. American Journal of Preventive Medicine. 2021;61(5, Supplement 1):S47-S54. https:\/\/doi.org\/10.1016\/j.amepre.2021.06.001","DOI":"10.1016\/j.amepre.2021.06.001"},{"key":"10384_CR16","unstructured":"Pearson C, Christopoulos K, Crouch PC et al. Impacy of Immediate ART for Patients with Known HIV Experiencing a Gap in HIV Care. Conference on Retroviruses and Opportunistic Infections; 2021. https:\/\/www.croiwebcasts.org\/console\/player\/47845?mediaType=slideVideo&"},{"issue":"18","key":"10384_CR17","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1056\/NEJMoa042291","volume":"352","author":"CD Pilcher","year":"2005","unstructured":"Pilcher CD, Fiscus SA, Nguyen TQ, et al. Detection of Acute infections during HIV Testing in North Carolina. N Engl J Med. 2005;352(18):1873\u201383. https:\/\/doi.org\/10.1056\/NEJMoa042291.","journal-title":"N Engl J Med"},{"issue":"2","key":"10384_CR18","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1097\/QAI.0b013e31827a0b0d","volume":"62","author":"KA Christopoulos","year":"2013","unstructured":"Christopoulos KA, Zetola NM, Klausner JD, et al. Leveraging a Rapid, Round-the-clock HIV testing system to screen for Acute HIV infection in a large Urban Public Medical Center. J Acquir Immune Defic Syndr. 2013;62(2):e30\u20138. https:\/\/doi.org\/10.1097\/QAI.0b013e31827a0b0d.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10384_CR19","unstructured":"Cepheid IVDMD, Xpert\u00ae. HIV-1 Viral Load - Instructions for Use. 301\u20133068, Rev. N. 2023-06."},{"key":"10384_CR20","unstructured":"Xpert\u00ae HIV-1 Viral Load. Accessed February 22. 2024. https:\/\/www.cepheid.com\/en-GB\/tests\/blood-virology-womens-health-sexual-health\/xpert-hiv-1-viral-load.html#nav-id-0"},{"key":"10384_CR21","unstructured":"PQDx. 0192, 0193, 0194, 0195-070-00_PQPR v 8.0.pdf. Accessed December 8, 2024. https:\/\/extranet.who.int\/prequal\/sites\/default\/files\/whopr_files\/PQDx%200192%2C%200193%2C%200194%2C%200195-070-00_PQPR%20v%208.0.pdf"},{"key":"10384_CR22","unstructured":"CDC. Test Complexities. Clinical Laboratory Improvement Amendments (CLIA). September 11, 2024. Accessed December 8. 2024. https:\/\/www.cdc.gov\/clia\/php\/test-complexities\/index.html"},{"issue":"2","key":"10384_CR23","doi-asserted-by":"publisher","first-page":"141","DOI":"10.11613\/BM.2015.015","volume":"25","author":"D Giavarina","year":"2015","unstructured":"Giavarina D. Understanding bland Altman analysis. Biochem Med (Zagreb). 2015;25(2):141\u201351. https:\/\/doi.org\/10.11613\/BM.2015.015.","journal-title":"Biochem Med (Zagreb)"},{"key":"10384_CR24","unstructured":"550880: Human Immunodeficiency Virus 1 (HIV-1), Quantitative, RNA (Abbott\u00ae RealTime) | Labcorp. Accessed February 22. 2024. https:\/\/www.labcorp.com\/tests\/550880\/human-immunodeficiency-virus-1-hiv-1-quantitative-rna-abbott-realtime"},{"key":"10384_CR25","unstructured":"Revised Recommendations for HIV Screening of Pregnant Women. Accessed February 22. 2024. https:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/rr5020a1.htm"},{"issue":"7","key":"10384_CR26","doi-asserted-by":"publisher","first-page":"e005670","DOI":"10.1136\/bmjgh-2021-005670","volume":"6","author":"F Naeem","year":"2021","unstructured":"Naeem F, Karellis A, Nair S, et al. Multiplexed technologies for sexually transmitted infections: global evidence on patient-centered and clinical health outcomes. BMJ Glob Health. 2021;6(7):e005670. https:\/\/doi.org\/10.1136\/bmjgh-2021-005670.","journal-title":"BMJ Glob Health"},{"key":"10384_CR27","unstructured":"Tsoi BW, Parker M, Fine SM et al. HIV Testing. Johns Hopkins University; 2022. Accessed September 17, 2024. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK581840\/"},{"key":"10384_CR28","unstructured":"Commissioner O of the. FDA Permits Marketing of First Point-of-Care Hepatitis C RNA Test. FDA. August 9. 2024. Accessed September 17, 2024. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-permits-marketing-first-point-care-hepatitis-c-rna-test"},{"issue":"4","key":"10384_CR29","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1071\/SH19233","volume":"17","author":"SFE Bell","year":"2020","unstructured":"Bell SFE, Coffey L, Debattista J, et al. Peer-delivered point-of-care testing for Chlamydia trachomatis and Neisseria gonorrhoeae within an urban community setting: a cross-sectional analysis. Sex Health. 2020;17(4):359. https:\/\/doi.org\/10.1071\/SH19233.","journal-title":"Sex Health"},{"key":"10384_CR30","doi-asserted-by":"publisher","first-page":"104281","DOI":"10.1016\/j.drugpo.2023.104281","volume":"123","author":"J Valencia","year":"2024","unstructured":"Valencia J, V\u00e1zquez L, Lazarus JV, et al. On-site testing and treatment of sexually transmitted infections among female sex workers using molecular point-of-care testing integrated into harm reduction services in Madrid, Spain. Int J Drug Policy. 2024;123:104281. https:\/\/doi.org\/10.1016\/j.drugpo.2023.104281.","journal-title":"Int J Drug Policy"},{"issue":"12","key":"10384_CR31","doi-asserted-by":"publisher","first-page":"e0144656","DOI":"10.1371\/journal.pone.0144656","volume":"10","author":"E Ardizzoni","year":"2015","unstructured":"Ardizzoni E, Fajardo E, Saranchuk P, et al. Implementing the Xpert\u00ae MTB\/RIF Diagnostic Test for Tuberculosis and Rifampicin Resistance: outcomes and lessons learned in 18 countries. PLoS ONE. 2015;10(12):e0144656. https:\/\/doi.org\/10.1371\/journal.pone.0144656.","journal-title":"PLoS ONE"},{"issue":"8","key":"10384_CR32","doi-asserted-by":"publisher","first-page":"CD012768","DOI":"10.1002\/14651858.CD012768.pub2","volume":"2018","author":"M Kohli","year":"2018","unstructured":"Kohli M, Schiller I, Dendukuri N, et al. Xpert\u00ae MTB\/RIF assay for extrapulmonary tuberculosis and rifampicin resistance. Cochrane Database Syst Rev. 2018;2018(8):CD012768. https:\/\/doi.org\/10.1002\/14651858.CD012768.pub2.","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"10384_CR33","doi-asserted-by":"publisher","first-page":"e0251858","DOI":"10.1371\/journal.pone.0251858","volume":"16","author":"S Kabir","year":"2021","unstructured":"Kabir S, Parash MTH, Emran NA, Hossain ABMT, Shimmi SC. Diagnostic challenges and Gene-Xpert utility in detecting Mycobacterium tuberculosis among suspected cases of Pulmonary Tuberculosis. PLoS ONE. 2021;16(5):e0251858. https:\/\/doi.org\/10.1371\/journal.pone.0251858.","journal-title":"PLoS ONE"},{"issue":"4","key":"10384_CR34","doi-asserted-by":"publisher","first-page":"e00812","DOI":"10.1128\/mBio.00812-17","volume":"8","author":"S Chakravorty","year":"2017","unstructured":"Chakravorty S, Simmons AM, Rowneki M, et al. The New Xpert MTB\/RIF Ultra: improving detection of Mycobacterium tuberculosis and Resistance to Rifampin in an assay suitable for point-of-care testing. mBio. 2017;8(4):e00812\u201317. https:\/\/doi.org\/10.1128\/mBio.00812-17.","journal-title":"mBio"},{"issue":"3","key":"10384_CR35","doi-asserted-by":"publisher","first-page":"CD013694","DOI":"10.1002\/14651858.CD013694.pub2","volume":"2021","author":"AE Shapiro","year":"2021","unstructured":"Shapiro AE, Ross JM, Yao M, et al. Xpert MTB\/RIF and Xpert Ultra assays for screening for pulmonary tuberculosis and rifampicin resistance in adults, irrespective of signs or symptoms. Cochrane Database Syst Rev. 2021;2021(3):CD013694. https:\/\/doi.org\/10.1002\/14651858.CD013694.pub2.","journal-title":"Cochrane Database Syst Rev"},{"key":"10384_CR36","doi-asserted-by":"publisher","first-page":"1149741","DOI":"10.3389\/fcimb.2023.1149741","volume":"13","author":"X Gong","year":"2023","unstructured":"Gong X, He Y, Zhou K, Hua Y, Li Y. Efficacy of Xpert in Tuberculosis diagnosis based on various specimens: a systematic review and meta-analysis. Front Cell Infect Microbiol. 2023;13:1149741. https:\/\/doi.org\/10.3389\/fcimb.2023.1149741.","journal-title":"Front Cell Infect Microbiol"},{"issue":"9","key":"10384_CR37","doi-asserted-by":"publisher","first-page":"CD013359","DOI":"10.1002\/14651858.CD013359.pub3","volume":"2022","author":"AW Kay","year":"2022","unstructured":"Kay AW, Ness T, Verkuijl SE, et al. Xpert MTB\/RIF Ultra assay for tuberculosis disease and rifampicin resistance in children. Cochrane Database Syst Rev. 2022;2022(9):CD013359. https:\/\/doi.org\/10.1002\/14651858.CD013359.pub3.","journal-title":"Cochrane Database Syst Rev"},{"key":"10384_CR38","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1186\/s12879-023-08459-7","volume":"23","author":"MH Bayan","year":"2023","unstructured":"Bayan MH, Smalls T, Boudreau A, et al. Evaluating the impact of point-of-care HIV viral load assessment on linkage to care in Baltimore, MD: a randomized controlled trial. BMC Infect Dis. 2023;23:570. https:\/\/doi.org\/10.1186\/s12879-023-08459-7.","journal-title":"BMC Infect Dis"},{"key":"10384_CR39","unstructured":"Jain V. RAPID-VL intervention improves viral load ordering, results turnaround time and viral suppression: a cluster randomized trial in HIV clinics in Uganda. Oral abstract sessions with live Q&A presented at: 11th International AIDS Society Conference on HIV Science; July 19, 2021; Virtual. https:\/\/theprogramme.ias2021.org\/Abstract\/Abstract\/2418."}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-024-10384-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-024-10384-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-024-10384-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T22:01:33Z","timestamp":1736200893000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-024-10384-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,6]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["10384"],"URL":"https:\/\/doi.org\/10.1186\/s12879-024-10384-2","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,6]]},"assertion":[{"value":"8 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the ethical principles outlined in the Declaration of Helsinki and was approved by the Institutional Review Board (IRB) at the University of California, San Francisco (UCSF).\u200b The study protocol was reviewed and approved under CHR# 18-25758. Informed consent was waived for study participants because remnant specimens were used, presenting minimal risk to participants and adhering to ethical guidelines while still respecting patient autonomy. Staff provided informed consent to participate in interviews outside of work hours and were compensated $50.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"We have received informed consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Christopoulos has been a medical advisory board member for Gilead Sciences and a workshop participant for Janssen.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"26"}}